Isoprenaline Only Product
Phase 3Small molecule
Isoprenaline Only Product is one of 23 small molecule programs targeting Cardiac Arrest. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Cardiac Arrest
#DrugCompanyPhaseTrials
1Brilinta
AstraZenecaApproved
Plavix
SanofiApproved
Neoral
NovartisApproved
Alka-Seltzer
AAbbott
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Ativan
BBausch Health Americas, Inc.
Approved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Kengreal
Chiesi Farmaceutici S.p.A.Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Isoprenaline Only Product. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Southern Denmark